CN101918446B - 抑制内皮唾液酸蛋白与配体结合的方法 - Google Patents

抑制内皮唾液酸蛋白与配体结合的方法 Download PDF

Info

Publication number
CN101918446B
CN101918446B CN200880011474.9A CN200880011474A CN101918446B CN 101918446 B CN101918446 B CN 101918446B CN 200880011474 A CN200880011474 A CN 200880011474A CN 101918446 B CN101918446 B CN 101918446B
Authority
CN
China
Prior art keywords
pro
thr
ser
gly
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200880011474.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN101918446A (zh
Inventor
周宇虹
布赖恩·E·汤姆克维兹
路易吉·格拉索
菲利普·M·萨斯
尼古拉斯·C·尼古拉德斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Corp of North America
Original Assignee
Morphotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek Inc filed Critical Morphotek Inc
Publication of CN101918446A publication Critical patent/CN101918446A/zh
Application granted granted Critical
Publication of CN101918446B publication Critical patent/CN101918446B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Flanged Joints, Insulating Joints, And Other Joints (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN200880011474.9A 2007-04-05 2008-04-04 抑制内皮唾液酸蛋白与配体结合的方法 Active CN101918446B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91036207P 2007-04-05 2007-04-05
US60/910,362 2007-04-05
US98002607P 2007-10-15 2007-10-15
US60/980,026 2007-10-15
PCT/US2008/059374 WO2008124570A1 (en) 2007-04-05 2008-04-04 Methods for inhibiting the binding of endosialin to ligands

Publications (2)

Publication Number Publication Date
CN101918446A CN101918446A (zh) 2010-12-15
CN101918446B true CN101918446B (zh) 2014-06-18

Family

ID=39714208

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880011474.9A Active CN101918446B (zh) 2007-04-05 2008-04-04 抑制内皮唾液酸蛋白与配体结合的方法

Country Status (20)

Country Link
US (4) US7807382B2 (enExample)
EP (2) EP2137217B1 (enExample)
JP (2) JP5825784B2 (enExample)
KR (1) KR101529334B1 (enExample)
CN (1) CN101918446B (enExample)
AU (1) AU2008237296B2 (enExample)
BR (1) BRPI0809665B8 (enExample)
CA (1) CA2682726C (enExample)
CY (2) CY1115370T1 (enExample)
DK (2) DK2137217T3 (enExample)
ES (2) ES2606906T3 (enExample)
HR (2) HRP20140266T1 (enExample)
HU (1) HUE031269T2 (enExample)
LT (1) LT2620451T (enExample)
MX (1) MX2009010701A (enExample)
PL (2) PL2137217T3 (enExample)
PT (2) PT2137217E (enExample)
RS (2) RS53362B (enExample)
SI (2) SI2137217T1 (enExample)
WO (1) WO2008124570A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006241235B2 (en) * 2005-04-22 2012-04-05 Eisai, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
RS53362B (sr) 2007-04-05 2014-10-31 Morphotek, Inc. Postupak inhibiranja vezivanja endosijalina na ligande
WO2009126725A1 (en) * 2008-04-09 2009-10-15 The Regents Of The University Of Michigan Method of modulating neovascularization
US20100260769A1 (en) * 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules
WO2011060233A1 (en) 2009-11-11 2011-05-19 The Trustees Of The University Of Pennsylvania Anti-tem1 antibodies and uses thereof
EP2621946A1 (en) 2010-09-29 2013-08-07 Morphotek, Inc. Engineered human endosialin-expressing rodents
US9139656B2 (en) 2012-03-30 2015-09-22 Morphotek, Inc. TEM-1 diagnostic antibodies
US9783610B2 (en) * 2012-04-27 2017-10-10 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
HK1219980A1 (zh) 2013-03-09 2017-04-21 Baylor College Of Medicine 靶向血管的t细胞疗法
GB201702926D0 (en) * 2017-02-23 2017-04-12 Univ Birmingham Modulators
IL272246B1 (en) 2017-07-28 2025-09-01 Applied Therapeutics Inc Derivatives of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as aldose reductase inhibitors in treating galactosemia or preventing complications associated with galactosemia
CN110531077B (zh) * 2018-05-25 2023-07-07 荣昌生物制药(烟台)股份有限公司 间皮素免疫组化检测试剂盒
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN113966396A (zh) 2019-05-07 2022-01-21 迈阿密大学 遗传性神经病和相关障碍的治疗和检测
CN111026023A (zh) * 2020-01-12 2020-04-17 安徽楚江科技新材料股份有限公司 基于s7-400控制系统的铜带轧机PLC组态方法
CN116790744B (zh) * 2023-06-30 2024-04-26 浙江大学 一种缺血性心脏病晚期纤维化干预靶点及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090930A (en) * 1994-03-08 2000-07-18 Ludwig Institute For Cancer Research Recombinant human anti-FB5 antibodies
WO2005086713A2 (en) * 2004-03-04 2005-09-22 Kirin Brewery Co., Ltd. Role of human endothelial precursor cells and vascular pericytes tumor in angiogenesis

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5342757A (en) 1992-11-13 1994-08-30 Ludwig Institute For Cancer Research Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof
WO1994018562A1 (en) 1993-02-05 1994-08-18 Epigen, Inc. Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6146894A (en) 1998-04-14 2000-11-14 The Johns Hopkins University Method for generating hypermutable organisms
EP1112020A1 (en) 1998-09-09 2001-07-04 U.S. Army Institute of Surgical Research Method for monitoring arterial oxygen saturation
AU2001248352A1 (en) * 2000-03-15 2001-09-24 Epigenomics Ag Diagnosis of diseases associated with the cell cycle
CA2416732C (en) * 2000-08-02 2016-02-09 Brad St. Croix Endothelial cell expression patterns
CA2434926C (en) 2001-01-15 2014-04-01 Morphotek, Inc. Chemical inhibitors of mismatch repair
US20040043928A1 (en) * 2001-08-02 2004-03-04 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040014058A1 (en) * 2001-10-05 2004-01-22 Alsobrook John P. Novel human proteins, polynucleotides encoding them and methods of using the same
WO2004016758A2 (en) * 2002-08-15 2004-02-26 Genzyme Corporation Brain endothelial cell expression patterns
US20040253606A1 (en) * 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
EP1599503B1 (en) 2003-03-04 2010-12-29 Kirin Beer Kabushiki Kaisha Endothelial cell specific antibodies and uses thereof
WO2006017759A2 (en) 2004-08-05 2006-02-16 Kirin Brewery Co., Ltd. Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof
WO2006029045A2 (en) 2004-09-03 2006-03-16 Kirin Brewery Co., Ltd. Endothelial cell specific antibodies and uses thereof
EP1793868B1 (en) * 2004-09-23 2010-12-29 Guerbet Liposomal contrast agents for cest imaging
EP1819736B1 (en) 2004-12-03 2010-08-04 Morphotek, Inc. Use of endosialin binding proteins to isolate endosialin positive cells
EP2011885B1 (en) * 2005-02-10 2015-04-22 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
AU2006241235B2 (en) * 2005-04-22 2012-04-05 Eisai, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
US7315372B1 (en) * 2005-09-29 2008-01-01 The United States Of America As Represented By The Secretary Of The Navy Instrument using near-field intensity correlation measurements for characterizing scattering of light by suspensions
DE102005050933A1 (de) * 2005-10-21 2007-04-26 Justus-Liebig-Universität Giessen Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen
US7908090B2 (en) * 2005-11-30 2011-03-15 The Board Of Trustees Of The Leland Stanford Junior University Signatures for human aging
KR20080087822A (ko) * 2005-12-16 2008-10-01 제넨테크, 인크. 신경아교종을 진단하고, 예측하고, 치료하는 방법
WO2008084331A2 (en) 2006-06-21 2008-07-17 Hopitaux Universitaires De Geneve Biomarkers for renal disorders
EP2041307A2 (en) * 2006-07-13 2009-04-01 Siemens Healthcare Diagnostics GmbH Prediction of breast cancer response to taxane-based chemotherapy
US20090176656A1 (en) * 2006-07-21 2009-07-09 Halloran Philip F Tissue rejection
EP2543739B1 (en) 2006-08-11 2015-07-22 Johns Hopkins University Consensus coding sequences of human colorectal cancers
US20080300170A1 (en) * 2006-09-01 2008-12-04 Cohava Gelber Compositions and methods for diagnosis and treatment for type 2 diabetes
US20100092476A1 (en) * 2006-11-17 2010-04-15 Hanash Samir M Pancreatic cancer biomarkers
US20110119776A1 (en) 2007-02-05 2011-05-19 Wong Kwok-Kin Methods of diagnosing and prognosing lung cancer
WO2008101118A2 (en) 2007-02-14 2008-08-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates
RS53362B (sr) * 2007-04-05 2014-10-31 Morphotek, Inc. Postupak inhibiranja vezivanja endosijalina na ligande
EP1986010A1 (en) 2007-04-05 2008-10-29 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Methods and tools for discriminating colorectal adenomas and adenocarcinomas
US9186405B2 (en) 2007-08-16 2015-11-17 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
ES2936256T3 (es) * 2008-02-01 2023-03-15 Massachusetts Gen Hospital Uso de microvesículas en el diagnóstico, y pronóstico de enfermedades y afecciones médicas
EP2250287B1 (en) 2008-02-19 2013-09-18 MDxHealth SA Detection and prognosis of lung cancer
US20110117111A1 (en) 2008-03-26 2011-05-19 Johns Hopkins University Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
WO2010033913A1 (en) * 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
WO2010045714A1 (en) 2008-10-20 2010-04-29 University Health Network Methods and compositions for the detection of ovarian cancer
CA2749601C (en) 2009-01-14 2020-07-21 Stephen M. Hewitt Ratio based biomarkers and methods of use thereof
US20100260769A1 (en) * 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090930A (en) * 1994-03-08 2000-07-18 Ludwig Institute For Cancer Research Recombinant human anti-FB5 antibodies
US6391302B1 (en) * 1994-03-08 2002-05-21 Ludwig Institute For Cancer Research Method for treating cancers which present antigen FB5 with humanized antibodies
WO2005086713A2 (en) * 2004-03-04 2005-09-22 Kirin Brewery Co., Ltd. Role of human endothelial precursor cells and vascular pericytes tumor in angiogenesis

Also Published As

Publication number Publication date
LT2620451T (lt) 2017-01-10
SI2137217T1 (sl) 2014-07-31
EP2620451B1 (en) 2016-09-14
BRPI0809665B8 (pt) 2021-05-25
US8895000B2 (en) 2014-11-25
CA2682726A1 (en) 2008-10-16
ES2452929T3 (es) 2014-04-03
US7807382B2 (en) 2010-10-05
HRP20140266T1 (hr) 2014-04-25
PT2137217E (pt) 2014-03-20
US20150079104A1 (en) 2015-03-19
PL2620451T3 (pl) 2017-06-30
WO2008124570A1 (en) 2008-10-16
KR20100016221A (ko) 2010-02-12
MX2009010701A (es) 2010-01-20
US20170029509A1 (en) 2017-02-02
BRPI0809665B1 (pt) 2021-03-23
CY1118592T1 (el) 2017-07-12
DK2137217T3 (en) 2014-03-17
PT2620451T (pt) 2016-12-20
PL2137217T3 (pl) 2014-08-29
HRP20161715T1 (hr) 2017-02-10
US20110033455A1 (en) 2011-02-10
AU2008237296A1 (en) 2008-10-16
KR101529334B1 (ko) 2015-06-16
JP2013150618A (ja) 2013-08-08
EP2137217A1 (en) 2009-12-30
JP5825784B2 (ja) 2015-12-02
US20080248034A1 (en) 2008-10-09
RS55447B1 (sr) 2017-04-28
US10053509B2 (en) 2018-08-21
JP2010523592A (ja) 2010-07-15
ES2606906T3 (es) 2017-03-28
CA2682726C (en) 2017-05-09
EP2620451A1 (en) 2013-07-31
RS53362B (sr) 2014-10-31
US9505842B2 (en) 2016-11-29
CY1115370T1 (el) 2017-01-04
BRPI0809665A2 (pt) 2018-12-04
AU2008237296B2 (en) 2013-07-04
DK2620451T3 (da) 2017-01-02
WO2008124570A8 (en) 2008-11-27
EP2137217B1 (en) 2014-03-05
HUE031269T2 (en) 2017-06-28
SI2620451T1 (sl) 2017-01-31
CN101918446A (zh) 2010-12-15

Similar Documents

Publication Publication Date Title
CN101918446B (zh) 抑制内皮唾液酸蛋白与配体结合的方法
CN113817061B (zh) 一种抗cld18a2单域抗体及其抗肿瘤用途
US11192953B2 (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
CN111954680B (zh) IL2Rβ/共同γ链抗体
KR20200035291A (ko) 인터류킨-21 뮤테인 및 치료 방법
KR20150023811A (ko) 암의 치료를 위한 lsr 항체 및 그의 용도
CN101189264A (zh) M-csf特异性单克隆抗体及其应用
KR20140029446A (ko) 면역 관련 장애 및 암의 치료를 위한 폴리펩티드 및 폴리뉴클레오티드, 및 이들의 용도
TW200823235A (en) Prophylactic and therapeutic agent for cancers
JP2012503984A (ja) ヒト抗ｐｄ−１、ｐｄ−ｌ１、及びｐｄ−ｌ２抗体とその用途
KR20130108430A (ko) 항-노치1 항체
KR20130066632A (ko) 치료적 저밀도 지단백질-관련 단백질 ６ （ｌｒｐ６） 항체에 대한 조성물 및 사용 방법
KR20200044899A (ko) 암의 치료 및 진단을 위한 tim-3 길항제
KR20200109339A (ko) Tim3에 대한 항체를 사용하여 암을 치료하는 방법
KR101809761B1 (ko) 세포 외 기질 단백질의 아미노산 서열 ｒｇｄ에 특이적인 인간화된 항체 및 그의 용도
CN114174536A (zh) 抗trem-1抗体及其用途
CN101316861A (zh) Il-17a和il-17f拮抗剂以及使用所述拮抗剂的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20181029

Address after: new jersey

Patentee after: Eisai Corp.

Address before: American Pennsylvania

Patentee before: Morphotek Inc.

TR01 Transfer of patent right